Navigation Links
Nfocus Neuromedical, Inc. Luna™ Aneurysm Embolization System Receives CE Mark
Date:2/15/2011

PALO ALTO, Calif., Feb. 15, 2011 /PRNewswire/ -- Nfocus Neuromedical, Inc., an innovative medical device company with a focus on the next generation treatment for brain aneurysms, announced today that its Luna™ Aneurysm Embolization System (AES) received CE Mark for the treatment of patients with brain aneurysms.  The Luna AES is designed to be a single-deployment, easy-to-use system for the treatment of brain aneurysms both pre- and post-rupture.  

"Brain aneurysm treatment historically has been the domain of either surgery or, more recently, catheter-placed wire coils," said Eric Milledge, CEO, Nfocus Neuromedical.  "Surgery can be traumatic and expensive, and coils may fail to fully treat an aneurysm.  The Luna AES represents a dramatic step forward in the treatment of these patients."

It is estimated that up to one in 15 people will develop a brain aneurysm during their lifetime.(1)  Rupture of an aneurysm can cause stroke, brain damage and even death.

The Luna AES treats brain aneurysms by blocking (embolizing) blood flow while providing a scaffold to encourage tissue growth across an aneurysm opening and create a plug. The Luna uses a self-expandable, multi-layer oval implant made from Nitinol, a nickel-titanium alloy. The properties of the device allow it to easily compress within a conventional catheter, and then rapidly and easily open to full size once deployed within an aneurysm.

"CE Mark approval is an important milestone for Nfocus," said Robert O'Holla, vice president of regulatory affairs, Nfocus Neuromedical.  "The Luna AES is our flagship product and we look forward to working with physicians and hospitals in Europe to advance this important new technology."

About Nfocus Neuromedical, Inc.

Nfocus is developing the next generation treatment for brain aneurysms. The company's innovative LUNA™ product is a single-deployment, easy-to-use embolization device designed to be a direct replacement to detachable coils. Nfocus is backed by three major U.S.- and OUS-based venture funds: DFJ ePlanet Capital, Technology Partners, and InCube Ventures. Other investors include Raffles Capital and Endeavor Vision. More information can be found at www.nfocusneuro.com.

(1) - http://www.brainaneurysm.com/


'/>"/>
SOURCE Nfocus Neuromedical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Nfocus Neuromedical Announces FDA 510(k) Clearance for Next Generation Device to Treat Vascular Lesions
2. Verathon(R) Helps Physicians Identify the Presence of Abdominal Aortic Aneurysms with New AortaScan(TM) Brand of Portable Ultrasound Aortic Measurement Instruments
3. Neurointerventionists Expand Research to Quality of Life in Aneurysm Patients Following Minimally Invasive Coiling Treatment
4. Boston Scientific Welcomes Results of Brain Aneurysm Clinical Trial
5. Advocate Christ Medical Center Using Glue-Like Liquid to Seal Off Brain Aneurysms
6. Valor Medical Reports Early Clinical Results of New Technology to Treat Cerebral Aneurysms
7. Valor Medical Announces First Human Implant of Neucrylate AN(TM) for Treatment of Cerebral Aneurysm
8. NeuroVasx, Inc. Announces $8.5 Million Private Placement and Completion of cPAX Aneurysm Treatment Study
9. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
10. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
11. Endovascular Forum and GEST Set Out on a Shared Venture to Bring the Highest Level of Embolization-based Scientific and Technical Education, Results, and Relevance for Patient Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... DUBLIN , April 20, 2017 ... "Latin America Pharmaceutical Contract Manufacturing Services Market Analysis By Service ... And Segment Forecasts, 2014 - 2025" report to their ... The Latin ... USD 21.0 billion by 2025 Low drug registration ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 ... Surgical drainage devices are tubes used to remove excess ... include, blood, serum, pus, urine, bile or lymph. Surgical ... types of surgery such as orthopedics surgery, cardiovascular surgery, ... device is prophylactic post-surgery to prevent accumulation of fluid ...
(Date:4/19/2017)... Companion animal vaccines ... pets such as canine, avian and feline. ... such as Attenuated Live Vaccines, Conjugate Vaccines, Inactivated ... Recombinant Vaccines. Attenuated live vaccines are derived from ... have been weakend under laboratory conditions. Conjugate vaccines ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... ... Miami native and local periodontist Dr. John Paul Gallardo is celebrating ... 1991 that this journey would have taken me into so many learning experiences both ... has pioneered implant dentistry innovation, evolving into an internationally recognized leader in the industry. ...
(Date:4/26/2017)... , ... April 26, 2017 , ... ... today launched a unique website ( CRISPRCas.pioneer.com ) that demonstrates how this advanced ... farmers produce more and better food, with fewer resources. It highlights the business’ ...
(Date:4/26/2017)... Doylestown, Pa. (PRWEB) , ... ... ... Solutions division, which provides an agile ecosystem and domain expertise for sponsors ... end-to-end, configurable randomization and trial supply management (RTSM) software platform. Bioclinica ...
(Date:4/25/2017)... ... April 25, 2017 , ... Bellus Medical, a ... first in a new class of photodynamic cosmetics (PDC). , Allumera® is the ... reduce outward signs of aging, and minimize the appearance of pores – all ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... agreement to be the preferred physical therapy provider for Derby City CrossFit, effective ... Derby City CrossFit as quickly and effectively as possible, ProRehab’s sports physical therapists ...
Breaking Medicine News(10 mins):